Sudarshan Pharma Industries Ltd (SUDARSHAN) Fair Value & Analysis
Basic Materials · IN · Market cap ₹9.9B
Risks
Fair value as of: Aug 13, 2026
From 14 valuation models · updated 7 days ago
Fair value updated Aug 13, 2026, revised from ₹15.87 to ₹15.34 (−3.3%) since Jul 6, 2026. Share price −9.3% over the past month.
Below-average quality, and screening another 60% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹19.83). The favourable scenario is already priced in.
- Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (₹10.74 to ₹19.83) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
41‑month range ₹5.10 – ₹51.83 · fair‑value band ₹10.74 – ₹19.83 · the ₹38.39 price screens above the ₹15.34 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sudarshan Pharma Industries Ltd (SUDARSHAN) currently trades at ₹38.39, while our model-based Fair Value estimate is ₹15.34, implying the stock looks roughly 60.0% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Sudarshan Pharma Industries Ltd generated revenue of ₹7.0B at a net margin of 3.3%. Revenue grew 36.7% year over year. It earns a return on equity of 16.2%. Net debt stands at ₹2.8B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹10.74 (bear case) to ₹19.83 (bull case); at ₹38.39, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 108% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -55% fair-value upside, at -60%, SUDARSHAN screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (₹20.77) versus Asset-Based (₹4.20). Highest evidence: Residual Income (76).
Notify me when SUDARSHAN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 34 · Market factors (momentum, volatility) 68
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sudarshan Pharma Industries Limited manufactures and sells specialty chemicals and intermediates for pharma, agro chemicals, coating, and various other industries in India. The company also focuses on manufactures active pharmaceuticals ingredients and vitamins manufacturing.
Full company description
Sudarshan Pharma Industries Limited manufactures and sells specialty chemicals and intermediates for pharma, agro chemicals, coating, and various other industries in India. The company also focuses on manufactures active pharmaceuticals ingredients and vitamins manufacturing. It also offers fine chemicals, solvents, agro chemicals, finish lubricants, inks, food colors, leather chemicals, oil field chemicals, lubricant specialties, paints and coatings, paper chemicals, personal and community hygiene products, pigments, polymers and additives, press room chemicals, sugar chemicals, textile chemicals, water treatment chemicals, rust preventives, metalworking fluids, PU additives, and other specialty chemicals. In addition, the company offers antibiotics, antifungal, anthelmintic medications, antihypertensive, anti-diabetic drugs, analgesics, neurotonics, antihistamines, and cough syrups, as well as manufactures and supplies chemicals and solvents. Further, it engages in the contract manufacturing and outsourcing and supply of generic pharma formulation and medicines to healthcare institution, government, NGO, and hospitals. The company also exports its products to the United Kingdom, Australia, Uzbekistan, Syria, Oman, Taiwan, the Middle East, and North Africa regions. Sudarshan Pharma Industries Limited was incorporated in 2008 and is headquartered in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sudarshan Pharma Industries Ltd reported revenue of ₹7.0B in FY2026 versus ₹3.6B in FY2022, a compound +18.5%/yr. Reported net income was ₹233M in FY2026, compounding +45.2%/yr from FY2022.
SUDARSHAN screens 60% overvalued. Compare with BASF SE →
Peer Group
Chemicals · 332 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| BASF SE BASN | 1,034 MXN | 467.04 MXN | -55% |
| PT Barito Pacific Tbk, BRPT | 1,855 IDR | 1,584 IDR | -15% |
| LG Chem, Ltd 051910 | 275,500 KRW | 587,755 KRW | +113% |
| SRF Limited 503806 | ₹2,609 | ₹749.17 | -71% |
| 542812 542812 | ₹4,709 | ₹791.05 | -83% |
| Navin Fluorine International Limited NAVINFLUOR | ₹8,357 | ₹2,146 | -74% |
| Deepak Nitrite Limited DEEPAKNI | ₹1,768 | ₹824.05 | -53% |
| 523642 523642 | ₹2,484 | ₹1,745 | -30% |
| 506285 506285 | ₹4,048 | ₹1,589 | -61% |
| Kansai Nerolac Paints Limited 500165 | ₹209.25 | ₹80.51 | -62% |
Compare Sudarshan Pharma Industries Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sudarshan Pharma Industries Ltd (SUDARSHAN) overvalued or undervalued?
What is the fair value of SUDARSHAN?
What is the quality score of SUDARSHAN?
What is the revenue of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
What is the net profit margin of SUDARSHAN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sudarshan Pharma Industries Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.